Egawa S
Department of Urology, Kitasato University School of Medicine.
Nihon Rinsho. 1998 Aug;56(8):2103-7.
Theoretical projected prostate cancer volume at the time of expected death was determined based on patient age and index cancer volume at diagnosis, assumed cancer volume doubling time and life expectancy of Japanese male population. Clinically insignificant cancer in 104 prostatectomy specimens was found to occur at 4.8, 10.6, 15.4 and 26.9% for tumor doubling times of 2, 3, 4 and 6 years, respectively. Assuming a 2-year doubling time with clinically insignificant cancer excluded, only 36.4% of significant cancers could be considered potentially curable and with a 3-year doubling time, 32.3%. For 4- and 6-year doubling times, only 30.7% and 25.0% of the clinically significant cancers were potentially curable, respectively. Patient life expectancy and tumor doubling time significantly determine the outcome of treatment for prostate cancer especially in elderly males with higher risk of mortality.
预期死亡时的理论预测前列腺癌体积是根据患者年龄、诊断时的索引癌体积、假定的癌体积倍增时间以及日本男性人口的预期寿命来确定的。在104份前列腺切除标本中，临床意义不显著的癌症在肿瘤倍增时间分别为2年、3年、4年和6年时的发生率分别为4.8%、10.6%、15.4%和26.9%。假设排除临床意义不显著的癌症后倍增时间为2年，只有36.4%的显著癌症可被认为有潜在治愈可能；倍增时间为3年时，这一比例为32.3%。对于4年和6年的倍增时间，临床上显著的癌症分别只有30.7%和25.0%有潜在治愈可能。患者的预期寿命和肿瘤倍增时间显著决定前列腺癌的治疗结果，尤其是在死亡风险较高的老年男性中。
